21
Participants
Start Date
September 18, 2019
Primary Completion Date
June 4, 2023
Study Completion Date
April 29, 2026
Biospecimen Collection
Undergo collection of blood samples
Brachytherapy
Undergo LDR brachytherapy
Cisplatin
Given IV
Computed Tomography
Undergo FDG-PET/CT
External Beam Radiation Therapy
Undergo pelvic EBRT
Fludeoxyglucose F-18
Undergo FDG-PET/CT
High-Dose Rate Brachytherapy
Undergo HDR brachytherapy
Intensity-Modulated Radiation Therapy
Undergo IMRT
Magnetic Resonance Imaging
Undergo MRI
Pharmacological Study
Correlative studies
Positron Emission Tomography
Undergo FDG-PET/CT
Triapine
Given IV and PO
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
University of Virginia Cancer Center, Charlottesville
VCU Massey Comprehensive Cancer Center, Richmond
University of Alabama at Birmingham Cancer Center, Birmingham
University of Kentucky/Markey Cancer Center, Lexington
University of Michigan Comprehensive Cancer Center, Ann Arbor
Wayne State University/Karmanos Cancer Institute, Detroit
Weisberg Cancer Treatment Center, Farmington Hills
University of Kansas Cancer Center, Kansas City
University of Kansas Clinical Research Center, Fairway
University of Kansas Hospital-Westwood Cancer Center, Westwood
University of Kansas Hospital-Indian Creek Campus, Overland Park
University of Oklahoma Health Sciences Center, Oklahoma City
Los Angeles General Medical Center, Los Angeles
USC / Norris Comprehensive Cancer Center, Los Angeles
Keck Medical Center of USC Pasadena, Pasadena
Rutgers Cancer Institute of New Jersey, New Brunswick
National Cancer Institute (NCI)
NIH